Navidea Biopharmaceuticals (NAVB) Highlights New Data for NAV4694 PET ß-Amyloid Imaging Agent Presented at AAIC 2013
7/22/2013 8:23:34 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea’s investigational Fluorine-18 labeled ß-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference (AAIC) in Boston, MA.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by